The Journal of Allergy and Clinical Immunology
Volume 118, Issue 2 , Pages 434-440 , August 2006

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis

  • Ronald Dahl, MD

      Affiliations

    • From the Department of Respiratory Diseases, Aarhus University Hospital
    • ,
  • Alexander Kapp, MD

      Affiliations

    • Department of Dermatology and Allergology, Hannover Medical University
    • ,
  • Giselda Colombo, MD

      Affiliations

    • Ospedale San Raffaele del Monte Tabor, Medicina Interna Allergologia, Milan
    • ,
  • Jan G.R. de Monchy, MD

      Affiliations

    • Division of Allergology, University of Groningen
    • ,
  • Sabina Rak, MD

      Affiliations

    • Section of Allergy, Sahlgrenska University Hospital, Gothenburg
    • ,
  • Waltraud Emminger, MD

      Affiliations

    • Allergie-Ambulatorium Rennweg, Vienna
    • ,
  • Montserrat Fernández Rivas, MD

      Affiliations

    • Fundación Hospital Alcorcón, Madrid
    • ,
  • Mette Ribel, MSc

      Affiliations

    • Group Clinical Development, ALK-Abelló A/S, Hørsholm
    • ,
  • Stephen R. Durham, MD

      Affiliations

    • Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London
    • Corresponding Author InformationReprint requests: Stephen R. Durham, MD, MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Head, Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Royal Brompton Hospital, Guy Scadding Building, Royal Brompton Campus, Dovehouse Street, SW3 6LY London, United Kingdom.

Received 20 February 2006 ,Revised 2 May 2006 ,Accepted 4 May 2006.

  • Image Result

    Consort flow diagram.

    Consort flow diagram.

  • Image Result

    Daily averaged grass pollen counts, scoring of symptoms, and scoring of rescue medication. P value presented for the comparison of the 2 treatment groups tested by ANOVA with the score as response var

    Daily averaged grass pollen counts, scoring of symptoms, and scoring of rescue medication. P value presented for the comparison of the 2 treatment groups tested by ANOVA with the score as response variable, treatment group as a fixed effect, and pollen region as random effect. Reduction was calculated as .

 Supported by ALK-Abelló A/S, Denmark.Disclosure of potential conflict of interest: S. R. Durham has consultant arrangements with, has received grant support from, and is on the speakers' bureau for ALK-Abelló. R. Dahl has consultant arrangements with Altana, GlaxoSmithKline, Boehringer Ingelheim, Novartis, and Fertin, and has received grant support from Altana, GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, ALK-Abelló, Roche, and Pfizer. A. Kapp has consultant arrangements with DPC, has received grant support from Novartis, Astellas, UCB, ALK-Abelló, and DPC, and is on the speakers' bureau for Nofartis, Astellas, UCB, and ALK-Abelló. S. Rak has received grant support from the Swedish Asthma and Allergy Association. M. Fernandez-Rivas has received grant support from the European Commission and the Instituto de Salud Carlos III of the Spanish Ministry of Health. M. Ribel is employed by ALK-Abelló A/S. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(06)01135-3

doi: 10.1016/j.jaci.2006.05.003

The Journal of Allergy and Clinical Immunology
Volume 118, Issue 2 , Pages 434-440 , August 2006

Article Tools

* Image Usage & Resolution